Raphael E. Steiner

Hematology | Oncology
1101 Hempstead Tpke
Uniondale, NY 11553

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Journal: Blood advances
Published: February 24, 2026

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Journal: Blood advances
Published: February 05, 2026

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Journal: Blood advances
Published: February 05, 2026

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma.

Journal: Blood cancer journal
Published: January 27, 2026

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Journal: Blood advances
Published: January 05, 2026

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Journal: Blood cancer journal
Published: September 13, 2025

A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis.

A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis.

Journal: American journal of hematology
Published: September 03, 2025

Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study.

Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study.

Journal: Leukemia & lymphoma
Published: August 06, 2025

Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.

Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.

Journal: Leukemia & lymphoma
Published: July 02, 2025

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma.

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma.

Journal: Nature communications
Published: April 18, 2025

Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.

Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.

Journal: Blood advances
Published: February 10, 2025

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 11, 2024
Showing 1-12 of 76

Last Updated: 09/26/2026